Avadel Pharmaceuticals (AVDL) Non-Current Debt (2016 - 2022)
Historic Non-Current Debt for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to $109.9 million.
- Avadel Pharmaceuticals' Non-Current Debt fell 2262.85% to $109.9 million in Q3 2022 from the same period last year, while for Sep 2022 it was $109.9 million, marking a year-over-year decrease of 2262.85%. This contributed to the annual value of $142.4 million for FY2021, which is 1106.54% up from last year.
- According to the latest figures from Q3 2022, Avadel Pharmaceuticals' Non-Current Debt is $109.9 million, which was down 2262.85% from $108.1 million recorded in Q2 2022.
- Over the past 5 years, Avadel Pharmaceuticals' Non-Current Debt peaked at $142.4 million during Q4 2021, and registered a low of $1.9 million during Q2 2020.
- In the last 5 years, Avadel Pharmaceuticals' Non-Current Debt had a median value of $115.7 million in 2018 and averaged $93.0 million.
- In the last 5 years, Avadel Pharmaceuticals' Non-Current Debt tumbled by 8802.48% in 2020 and then soared by 730721.0% in 2021.
- Quarter analysis of 5 years shows Avadel Pharmaceuticals' Non-Current Debt stood at $115.7 million in 2018, then rose by 5.14% to $121.7 million in 2019, then rose by 5.36% to $128.2 million in 2020, then increased by 11.07% to $142.4 million in 2021, then dropped by 22.8% to $109.9 million in 2022.
- Its Non-Current Debt was $109.9 million in Q3 2022, compared to $108.1 million in Q2 2022 and $116.5 million in Q1 2022.